The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Primum
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; Foundation Medicine; Merus NV
Speakers' Bureau - Bayer; Daiichi Sankyo/Astra Zeneca; Merus NV; Natera; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); BioXCel therapeutics (Inst); Immune System Key (Inst); Ipsen (Inst); Merck (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Merus NV
 
Alexander Lekan
No Relationships to Disclose
 
Allison Fitzgerald
No Relationships to Disclose
 
Zoe Malchiodi
No Relationships to Disclose
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Anteneh A. Tesfaye
Consulting or Advisory Role - Exelixis; Ipsen
 
Ming Tony Tan
Honoraria - AstraZeneca; Incyte; Otsuka; Sanofi Pasteur
Consulting or Advisory Role - American Gene Technologies
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Otsuka
 
Marcus Smith Noel
Consulting or Advisory Role - Celgene; Ipsen; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Daiichi Sankyo/Astra Zeneca; Taiho Pharmaceutical
Research Funding - ERYTECH Pharma
 
Aiwu Ruth He
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Genentech/Roche
Speakers' Bureau - AstraZeneca; bms; Eisai
Research Funding - AstraZeneca; Genentech; Merck
 
Reetu Mukherji
Research Funding - Genentech (Inst); Natera (Inst)
 
John Marshall
Employment - Caris Life Sciences; Indivumed
Leadership - 2curex
Honoraria - AstraZeneca/MedImmune; Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Seagan; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Genentech/Roche; Merck; Pfizer; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Caris Life Sciences; Merck; Pfizer; Seagan; Taiho Pharmaceutical
Research Funding - Genentech; Natera
 
Princess Jones
No Relationships to Disclose
 
Pascal Borderies
Employment - BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics
 
Vincent O'Neill
Employment - BioXcel Therapeutics
Leadership - BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics
 
Louis M. Weiner
Stock and Other Ownership Interests - Celldex; CytomX Therapeutics; Immunome; SIRPant Immunotherapeutics
Consulting or Advisory Role - CytomX Therapeutics; Immunome; SIRPAN
Research Funding - BioExcel
Patents, Royalties, Other Intellectual Property - Patent licensed to Merrimack Pharmaceuticals